Literature DB >> 16257833

Arylamine N-acetyltransferases: what we learn from genes and genomes.

Sotiria Boukouvala1, Giannoulis Fakis.   

Abstract

Arylamine N-acetyltransferases (NATs) are phase II xenobiotic metabolizing enzymes, catalyzing acetyl-CoA-dependent N- and O-acetylation reactions. All NATs have a conserved cysteine protease-like Cys-His-Asp catalytic triad inside their active site cleft. Other residues determine substrate specificity, while the C-terminus may control hydrolysis of acetyl-CoA during acetyltransfer. Prokaryotic NAT-like coding sequences are found in >30 bacterial genomes, including representatives of Actinobacteria, Firmicutes and Proteobacteria. Of special interest are the nat genes of TB-causing Mycobacteria, since their protein products inactivate the anti-tubercular drug isoniazid. Targeted inactivation of mycobacterial nat leads to impaired mycolic acid synthesis, cell wall damage and growth retardation. In eukaryotes, genes for NAT are found in the genomes of certain fungi and all examined vertebrates, with the exception of canids. Humans have two NAT isoenzymes, encoded by highly polymorphic genes on chromosome 8p22. Syntenic regions in rodent genomes harbour two Nat loci, which are functionally equivalent to the human NAT genes, as well as an adjacent third locus with no known function. Vertebrate genes for NAT invariably have a complex structure, with one or more non-coding exons located upstream of a single, intronless coding region. Ubiquitously expressed transcripts of human NAT1 and its orthologue, murine Nat2, are initiated from promoters with conserved Sp1 elements. However, in humans, additional tissue-specific NAT transcripts may be expressed from alternative promoters and subjected to differential splicing. Laboratory animals have been widely used as models to study the effects of NAT polymorphism. Recently generated knockout mice have normal phenotypes, suggesting no crucial endogenous role for NAT. However, these strains will be useful for understanding the involvement of NAT in carcinogenesis, an area extensively investigated by epidemiologists, often with ambiguous results.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257833     DOI: 10.1080/03602530500251204

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  38 in total

1.  Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter.

Authors:  Barbara Bonamassa; Yongjie Ma; Dexi Liu
Journal:  AAPS J       Date:  2012-05-30       Impact factor: 4.009

2.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

3.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

4.  Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2.

Authors:  Jason M Walraven; Mark A Doll; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2006-07-07       Impact factor: 4.030

5.  Polymorphisms in xenobiotic metabolizing genes, intakes of heterocyclic amines and red meat, and postmenopausal breast cancer.

Authors:  Hae-Jeung Lee; Kana Wu; David G Cox; David Hunter; Susan E Hankinson; Walter C Willett; Rashmi Sinha; Eunyoung Cho
Journal:  Nutr Cancer       Date:  2013-10-07       Impact factor: 2.900

6.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

Review 7.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

8.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

9.  Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat.

Authors:  David F Barker; Jason M Walraven; Elizabeth H Ristagno; Mark A Doll; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

10.  Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat.

Authors:  David W Hein; Jean Bendaly; Jason R Neale; Mark A Doll
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.